Clinical trial of risedronate in Japanese volunteers: A study on the effects of timing of dosing on absorption

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 2, 2004, Pages 120-126

  Ogura, Yasuhiko ^a   Gonsho, Akinori ^a   Cyong, Jong Chol ^b   Orimo, Hajime ^c  

^a Pharmaceutical Company   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Bisphosphonate; NE 58095; Osteoporosis; Risedronate (risedronate sodium hydrate)

Indexed keywords

BETA 2 MICROGLOBULIN; CALCIUM ION; CREATINE KINASE BB; RISEDRONIC ACID;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG URINE LEVEL; EPIGASTRIC PAIN; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; MEAL; MULTIPLE DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; EATING; ETIDRONIC ACID; HUMANS; INTESTINAL ABSORPTION; JAPAN; MALE; OSTEOPOROSIS; TIME FACTORS;

EID: 1642504774     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-003-0459-x     Document Type: Article

References (12)

1. Consensus Development Conference (1994) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650
2. Orimo H, Ohta H, Kishimoto H, Shiraki M, Suzuki T, Takaoka K, Nakamura T, Nishizawa Y, Hagino H, Hayashi Y, Hirota T, Fukunaga M, Hosoi T, Matsumoto T, Miki T, Yoh K, Wada S (2002) Guidelines for the treatment (pharmacotherapy) of osteoporosis - year 2000 revision (in Japanese). Osteoporosis Jpn 10:635-709
3. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
4. Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Nakatsuka K, Miura M (2001) Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone Miner Metab 19:338-344
5. Kawashima H (1993) Specificity of bisphosphonates' effect and bone metabolism (in Japanese). In: Fujita T (ed) Osteoporosis: diagnosis and treatment. Life Science Publishing, Tokyo, pp 397-408
6. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA (1989) Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 15:389-396
7. Fleisch H (2000) Bisphosphonates in Bone Disease, 4th edn. Academic Press, San Diego, pp 56-57
8. Mitchell DY, Heise MA, Pallone KA, Clay ME, Nesbitt JD, Russell DA, Melson CW (1999) The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 48:536-542
9. Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 22:111-118
10. DeSilva BS, Whitham DJ, Bhullar B, Kamra LC, DeStefano AJ (1998) Validation of an enzyme-linked immunosorbent assay for the determination of risedronate in human serum. AAPS PharmSci 1:S26. http://www.aapspharmsci.org/
11. Lin JH (1996) Bisphosphonates: a review of their pharmaco-kinetic properties. Bone (NY) 18:75-85
12. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298